CTLA-4: From conflict to clinic

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) identified in 1991 as a T cell costimulation ligand B7 receptor.
• Initial research faced uncertainties regarding its biological function.
• Confirmed in 1995 as a critical inhibitor of T cell responses.

Purpose of the Study:

• To elucidate the biological function of CTLA-4.
• To highlight the therapeutic potential of targeting CTLA-4.
• To underscore its role in immune regulation.

Main Methods:

• Receptor identification and characterization.
• Functional assays to determine T cell response modulation.
• Clinical application studies for therapeutic targeting.

Main Results:

• CTLA-4 confirmed as an inhibitor of T cell activation and proliferation.
• Demonstrated efficacy of CTLA-4 as a target in preclinical and clinical antitumor therapy.
• Established CTLA-4 as a soluble inhibitor for managing autoimmune conditions.

Conclusions:

• CTLA-4 plays a crucial role in immune system regulation.
• Targeting CTLA-4 offers a viable strategy for cancer immunotherapy.
• CTLA-4 inhibition is effective in controlling autoimmune diseases.